Psychedelics – News and Features

Researchers have shed light on how some psychedelic drugs – which show promise in patients with neuropsychiatric disorders such as depression and anxiety – bind to and activate serotonin receptors.

A meta-analysis of trials testing psilocybin-based treatments for depression has "encouraging" results. Here, we speak with the co-author of the study to learn more about how it was conducted, the key findings and implications for clinical implementation of psychedelic-based treatments.

This article explores the need to deregulate certain psychedelic drugs, including MDMA and psilocybin, which could help people living with PTSD and treatment-resistant depression as pharmaceutical treatments to retrain neural pathways and improve these conditions.

Dr. Schlag, acting CEO of Drug Science, discusses how the research group's work rises above traditional drug messaging.

Commonly referred to as “magic mushrooms,” psilocybin is a promising alternative treatment for people with medication-resistant depression and anxiety.

A single low dose of esketamine – the active form of the anesthetic drug, ketamine – can reduce depressive episodes when given immediately after childbirth, a new study has found.

New research has shown how blocking the activity of the Tiam1 enzyme in certain spinal neurons could reduce morphine tolerance and prolong the usefulness of morphine for pain relief.

Researchers have identified multiple brain regions that are unique to regulating emotions. The study is among the first of its kind to separate activity relating to emotion generation from emotion regulation in the human brain.

The hype and promise around psychedelic drug trials have accelerated legislation to liberalize access to these compounds. In this article, we delve into the pivotal events in psychedelic science that researchers in the field predict will shape the year 2024.

New treatments for depression are needed that act rapidly and also have sustained effects. Ketamine could be the answer.